Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Cellular Immunotherapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
5.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
5.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1 By Therapy Type
5.3.2 By Indication
5.3.3 By End-Use
5.3.4 By Region
6. North America Cellular Immunotherapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
6.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
6.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Cellular Immunotherapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy Type
6.3.1.2.2. By Indication
6.3.1.2.3. By End-Use
6.3.2. Canada Cellular Immunotherapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy Type
6.3.2.2.2. By Indication
6.3.2.2.3. By End-Use
6.3.3. Mexico Cellular Immunotherapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy Type
6.3.3.2.2. By Indication
6.3.3.2.3. By End-Use
7. Europe Cellular Immunotherapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
7.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
7.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Cellular Immunotherapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy Type
7.3.1.2.2. By Indication
7.3.1.2.3. By End-Use
7.3.2. Germany Cellular Immunotherapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy Type
7.3.2.2.2. By Indication
7.3.2.2.3. By End-Use
7.3.3. United Kingdom Cellular Immunotherapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy Type
7.3.3.2.2. By Indication
7.3.3.2.3. By End-Use
7.3.4. Italy Cellular Immunotherapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy Type
7.3.4.2.2. By Indication
7.3.4.2.3. By End-Use
7.3.5. Spain Cellular Immunotherapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy Type
7.3.5.2.2. By Indication
7.3.5.2.3. By End-Use
8. Asia-Pacific Cellular Immunotherapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
8.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
8.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Cellular Immunotherapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy Type
8.3.1.2.2. By Indication
8.3.1.2.3. By End-Use
8.3.2. India Cellular Immunotherapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy Type
8.3.2.2.2. By Indication
8.3.2.2.3. By End-Use
8.3.3. Japan Cellular Immunotherapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy Type
8.3.3.2.2. By Indication
8.3.3.2.3. By End-Use
8.3.4. South Korea Cellular Immunotherapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy Type
8.3.4.2.2. By Indication
8.3.4.2.3. By End-Use
8.3.5. Australia Cellular Immunotherapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy Type
8.3.5.2.2. By Indication
8.3.5.2.3. By End-Use
9. South America Cellular Immunotherapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
9.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
9.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Cellular Immunotherapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy Type
9.3.1.2.2. By Indication
9.3.1.2.3. By End-Use
9.3.2. Argentina Cellular Immunotherapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy Type
9.3.2.2.2. By Indication
9.3.2.2.3. By End-Use
9.3.3. Colombia Cellular Immunotherapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy Type
9.3.3.2.2. By Indication
9.3.3.2.3. By End-Use
10. Middle East and Africa Cellular Immunotherapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
10.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
10.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Cellular Immunotherapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy Type
10.3.1.2.2. By Indication
10.3.1.2.3. By End-Use
10.3.2. Saudi Arabia Cellular Immunotherapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy Type
10.3.2.2.2. By Indication
10.3.2.2.3. By End-Use
10.3.3. UAE Cellular Immunotherapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy Type
10.3.3.2.2. By Indication
10.3.3.2.3. By End-Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Cellular Immunotherapy Market: SWOT Analysis
14. Porter?s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Bristol-Myers Squibb Company.
15.1.1. Business Overview
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Novartis AG.
15.3. Gilead Sciences Inc. (Kite Pharma)
15.4. F. Hoffmann-La Roche Ltd.
15.5. Merck KGaA.
15.6. GlaxoSmithKline plc.
15.7. AstraZeneca Plc.
15.8. Pfizer Inc.
15.9. Johnson & Johnson.
15.10. Celyad.
16. Strategic Recommendations